Pfizer withdraws hypertension drug Thelin
December 14, 2010Sales and Marketing PAH, Pfizer, Thelin, liver damage, liver toxicity, patient safety, pulmonary arterial hypertension, sitaxentan
Pfizer has suffered a blow to its drug development programme with the withdrawal of pulmonary arterial hypertension (PAH) brand Thelin …
McNeil recalls Rolaids on particle contamination
December 14, 2010Manufacturing and Production J&J, JJ, McNeil, Rolaids, particulate contamination, pharmaceutical manufacturing, product recalls
Recalls at Johnson & Johnson are coming thick and fast at the moment. In the latest incident the firm’s troubled …
Sopharma breaks ground on 16th manufacturing plant
December 14, 2010Manufacturing and Production Bulgaria, Sopharma, oral dosage forms, pharma manufacturing, pharmaceutica production
Bulgarian drugmaker Sopharma says it will press ahead with plans to build a new production plant for oral dosage forms …
Sanofi extends Genzyme share deal deadline
December 14, 2010Manufacturing and Production, Research and Development, Sales and Marketing Genzyme, Sanofi, Sanofi-Aventis, mergers and acquisitions, pharma acquisitions
Sanofi-Aventis has extended the deadline to acquire Genzyme after the US biotech’s shareholders have so far proved immune to its …
Amgen and Actelion meet to “talk takeover”
December 13, 2010Research and Development, Sales and Marketing Acelion, Amgen, pharma acquisitions, takeover
Amgen has met with Actelion to discuss a potential takeover but has not yet made a bid for the Swiss …
Novartis pulls Zometa submission after breast cancer failure
December 13, 2010Research and Development, Sales and Marketing Novatis, Zometa, breast cancer, zoledronic
Novartis has pulled Zometa’s marketing application for an early breast cancer indication after the drug failed to meet its primary …
China to ‘overtake US in innovation by 2020’
December 13, 2010Research and Development, Sales and Marketing AstraZeneca, China, India, innovation
China will replace the US as the number one ‘powerhouse of innovation’ within the next ten years according to a …
Bristol-Myers Squibb appoints new UK general manager
December 13, 2010Manufacturing and Production, Research and Development, Sales and Marketing Amadou Diarra, BMS, Bristol-Myers Squibb, appointment, recruitment, sales and marketing
Bristol-Myers Squibb has appointed Amadou Diarra as general manager of its UK company, where he will be in charge of …
West Pharma cuts staff as profits are pressured
December 13, 2010Manufacturing and Production West Pharma, drug delivery systems, job cuts, pharma packaging, pharmaceutical manufacturing, plastic packaging
West Pharmaceutical Services has taken the axe to its manufacturing facilities in the US and UK in order to cut …
Contract manufacturing driving Indian bulk drugs market
December 13, 2010Manufacturing and Production Cygnus, Drug Master Files, India, Indian pharmaceutical industry, contract manufacturing
The Indian bulk drug industry is expected to expand at an annual growth rate of 21% to reach $16.91 billion …
Pfizer: WikiLeaks claims “preposterous”
December 10, 2010Research and Development Nigeria, Pfizer, Trovan, WikiLeaks, ceftriaxone, clinical trial safety, industry reputation
Pfizer has dimissed as “preposterous” the claims it hired investigators to uncover evidence of corruption by a top government official …
Double blow to Pfizer’s emerging markets strategy
December 10, 2010Business Services, Sales and Marketing David Simmons, Ian Read, Jean-Michel Halfon, Jeffrey Kindler, Pfizer, Steve Yang, emerging pharma markets, recruitment
Pfizer has lost two senior executives with key roles in its emerging markets strategy. The departure of the company’s head …
Hormone therapy drugs ‘increase heart disease risk’
December 10, 2010Research and Development AstraZeneca, Hormone therapy, Novartis, Pfizer, aromatase inhibitors, breast cancer, tamoxifen
Three aromatase inhibitors could increase the risk of heart disease in postmenopausal women with breast cancer, according to new data. …
Elan names Robert Ingram as new chairman
December 10, 2010Research and Development, Sales and Marketing Elan, appointment, research and development, sales and marketing
Elan has appointed former Glaxo Wellcome chief executive Robert Ingram as its chairman-designate. Ingram led Glaxo between 1997 and 2000 …
Valuing medicines and NHS reform – the ABPI view
December 10, 2010Sales and Marketing ABPI, NHS reforms, Paul Catchpole, market access, value-based pricing
For those concerned with improving the value for money of medicines to the UK’s health service, the government’s White Paper …
Boehringer puts afatinib head-to-head with Herceptin
December 10, 2010Research and Development BIBW 2992, Boehringer Ingelheim, Herceptin, Roche, Tovok, afatinib, breast cancer
Boehringer Ingelheim has set up a showdown between one of its pipeline oncology products and Roche’s Herceptin. It has started …
SHL Establishes New Facility in the USA for Final Assembly and Packaging of Auto-Injectors
December 10, 2010Manufacturing and Production auto injector, autoinjector, final assembly, packaging, shl
SHL, a leading manufacturer of drug delivery devices, will further expand operations in the USA with the establishment of SHL …
Roche highlights R&D promise after setbacks
December 9, 2010Research and Development MS, Roche, oncology, personalised medicine, schizophrenia
Roche has presented its pipeline to shareholders to boost confidence that it can sustain the spectacular growth of recent years. …
First GP consortia named
December 9, 2010Sales and Marketing Lansley, NHS, consortia, reforms
The first consortia of GPs who will spearhead England’s healthcare reforms have been unveiled. A total of 52 consortia from …
Digital Pharma: AZ launches its first UK iPhone app
December 8, 2010Medical Communications Apple, AstraZeneca, Digital Pharma blog, apps, ipad, iphone
AstraZeneca has launched an iPhone app to provide UK healthcare professionals with information on genetic tests for lung cancer. The …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
